Interstitial Lung Disease Section

Positive results from the TETON trials and expanding treatment options are encouraging for pulmonologists who are used to working with a limited toolkit for slowing disease progression in their patients with IPF.

A new consensus statement from the American Thoracic Society and the European Respiratory Journal introduces ILD terminology such as bronchiolocentric interstitial pneumonia and alveolar macrophage pneumonia.

New guidelines from ATS outline the screening and follow-up procedures for interstitial lung abnormalities as well as define who is at higher risk for progressing to ILD.

AI shows promise in improving ILD diagnosis, prognosis, and treatment decisions by analyzing complex data and patterns, though certain limitations hinder its clinical adoption.

Interstitial lung diseases (ILDs) are a diverse group of relentlessly progressive fibroinflammatory disorders. Pharmacotherapy includes antifibrotics and immunosuppressants as foundational strategies to mitigate loss of lung function. There has been a growing interest in telomere length and its response to immunosuppression in the ILD community. Telomeres are repetitive nucleotide sequences that “cap” chromosomes and protect…

Interstitial lung diseases (ILD) are a heterogeneous group of fibro-inflammatory disorders that can be progressive despite available therapies. The cornerstones of pharmacologic therapy include immunosuppression and antifibrotics. Data on the use of rituximab, a B-lymphocyte-depleting monoclonal antibody, often utilized as rescue therapy in progressive and severe ILD, was limited until recently. The RECITAL trial reported…